In8Bio (INAB) Return on Equity [ROE] (2021 - 2026)
In8Bio's Return on Equity [ROE] was -88.14% in Q2 2026, up 73.87 percentage points from -162.01% a year earlier but down 14.67 percentage points from the prior quarter.
Powered by 
Analysis
In8Bio (INAB) Return on Equity [ROE] (2021 - 2026) Analysis & Trends
For FY2025, Return on Equity [ROE] at In8Bio came in at -90.49%, up 62.79 percentage points from FY2024.
- In earlier years, Return on Equity [ROE] was -153.28% in FY2024 (-27.38 pp) and -125.90% in FY2023.
- Quarterly Return on Equity [ROE] has moved between -603.63% (Q4 2021) and -73.47% (Q1 2026) over five years.
- Compared with a year earlier, Return on Equity [ROE] has increased for five straight quarters, with an average year-over-year change of +30.73 percentage points over the last eight quarters.
- The best year-over-year quarter for Return on Equity [ROE] over five years was Q4 2022 (a gain of 494.55 percentage points); the worst was Q3 2024 (a drop of 132.82 percentage points).
- Per Business Quant data, INAB's Return on Equity [ROE] in the three quarters before Q2 2026 was -73.47% (Q1 2026), -93.35% (Q4 2025) and -142.56% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,199.50 Bn | 1,168.08 Bn | 19.71 Bn | 82.09% |
| 2 | Johnson & Johnson | 635.17 Bn | 555.03 Bn | 17.30 Bn | 19.33% |
| 3 | AbbVie | 504.69 Bn | 477.85 Bn | 12.70 Bn | - |
| 4 | Merck | 358.43 Bn | 312.86 Bn | 12.21 Bn | 7.21% |
| 5 | Novartis Ag | 288.36 Bn | 252.75 Bn | 11.24 Bn | 31.52% |
| 6 | Astrazeneca | 265.78 Bn | 239.54 Bn | 12.86 Bn | 21.39% |
| 7 | Amgen | 237.46 Bn | 192.86 Bn | 7.24 Bn | 83.75% |
| 8 | Gilead Sciences | 193.65 Bn | 167.76 Bn | 6.22 Bn | -18.38% |
| 9 | Pfizer | 171.05 Bn | 118.00 Bn | 10.94 Bn | 4.97% |
| 10 | In8Bio | 20.44 Mn | -57.91 Mn | - | -88.14% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -88.14% |
| Mar 31, 2026 | -73.47% |
| Dec 31, 2025 | -93.35% |
| Sep 30, 2025 | -142.56% |
| Jun 30, 2025 | -162.01% |
| Mar 31, 2025 | -191.63% |
| Dec 31, 2024 | -261.92% |
| Sep 30, 2024 | -285.55% |
| Jun 30, 2024 | -204.29% |
| Mar 31, 2024 | -145.83% |
| Dec 31, 2023 | -140.56% |
| Sep 30, 2023 | -152.73% |
| Jun 30, 2023 | -157.76% |
| Mar 31, 2023 | -151.32% |
| Dec 31, 2022 | -109.08% |
| Sep 30, 2022 | -94.68% |
| Jun 30, 2022 | -75.97% |
| Dec 31, 2021 | -603.63% |
| Sep 30, 2021 | -101.98% |
API Access
In8Bio Return on Equity [ROE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=INAB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-equity-[roe]", "ticker": "INAB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=INAB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();